aldosterone has been researched along with Vascular Diseases in 42 studies
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 7.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Primary aldosteronism not only results in hypertension but also stiffer arteries." | 5.43 | Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients. ( Chang, YY; Ho, YL; Hung, CS; Liao, CW; Lin, LY; Lin, YH; Lin, YT; Satoh, F; Wang, SM; Wu, KD; Wu, VC, 2016) |
| "Primary aldosteronism (PA) is associated with a higher incidence of cardiovascular events, probably through mineralocorticoid receptor (MR)-dependent endothelial cell dysfunction, in comparison with essential hypertension (EH)." | 5.37 | Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. ( Chen, JW; Chen, YL; Huang, PH; Kuo, CC; Kuo, YS; Lee, BC; Liang, CJ; Lin, SJ; Lin, SL; Lin, YH; Lo, SC; Sun, YY; Tsai, CT; Wu, EL; Wu, KD; Wu, VC, 2011) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 3.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "The pathophysiology of preeclampsia (PE) remains unclear." | 1.56 | An alternative splicing variant of mineralocorticoid receptor discovered in preeclampsia tissues and its effect on endothelial dysfunction. ( Chan, HC; Chen, H; Guo, M; Huang, H; Jin, L; Lin, X; Liu, X; Rahman, TU; Ruan, Y; Sheng, J; Tang, L; Ullah, K; Wang, Y; Wu, D; Wu, Y; Xu, G; Yu, P; Yu, Y; Zhou, C, 2020) |
| "Microalbuminuria was determined from 24-hour urine collections." | 1.48 | Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals. ( Anyfanti, P; Douma, S; Gavriilaki, E; Gkaliagkousi, E; Lazaridis, A; Nikolaidou, B; Triantafyllou, A; Vamvakis, A, 2018) |
| "Primary aldosteronism not only results in hypertension but also stiffer arteries." | 1.43 | Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients. ( Chang, YY; Ho, YL; Hung, CS; Liao, CW; Lin, LY; Lin, YH; Lin, YT; Satoh, F; Wang, SM; Wu, KD; Wu, VC, 2016) |
| "Primary aldosteronism (PA) is associated with a higher incidence of cardiovascular events, probably through mineralocorticoid receptor (MR)-dependent endothelial cell dysfunction, in comparison with essential hypertension (EH)." | 1.37 | Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. ( Chen, JW; Chen, YL; Huang, PH; Kuo, CC; Kuo, YS; Lee, BC; Liang, CJ; Lin, SJ; Lin, SL; Lin, YH; Lo, SC; Sun, YY; Tsai, CT; Wu, EL; Wu, KD; Wu, VC, 2011) |
| "Aldosterone is a steroid hormone that signals through renal mineralocorticoid receptors (MRs) to regulate blood pressure." | 1.36 | Placental growth factor mediates aldosterone-dependent vascular injury in mice. ( Aronovitz, M; Carmeliet, P; Ehsan, A; Jaffe, IZ; McGraw, AP; Mendelsohn, ME; Mohammad, NN; Newfell, BG; Perreault, RE, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (30.95) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 10 (23.81) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Rivera, A | 1 |
| Vega, C | 1 |
| Ramos-Rivera, A | 1 |
| Maldonado, ER | 1 |
| Prado, GN | 1 |
| Karnes, HE | 1 |
| Fesko, YA | 1 |
| Snyder, LM | 1 |
| Alper, SL | 1 |
| Romero, JR | 1 |
| Faulkner, JL | 2 |
| Belin de Chantemèle, EJ | 2 |
| Kumar, A | 1 |
| Patel, DR | 1 |
| Brennan, DM | 1 |
| Wolski, KE | 1 |
| Lincoff, AM | 1 |
| Ruotolo, G | 1 |
| McErlean, E | 1 |
| Weerakkody, G | 1 |
| Riesmeyer, JS | 1 |
| Nicholls, SJ | 1 |
| Nissen, SE | 1 |
| Menon, V | 1 |
| Lluch, E | 1 |
| Kennard, S | 1 |
| Antonova, G | 1 |
| Jaffe, IZ | 4 |
| Rodrigues, D | 1 |
| Costa, TJ | 1 |
| Silva, JF | 1 |
| Neto, JTO | 1 |
| Alves, JV | 1 |
| Fedoce, AG | 1 |
| Costa, RM | 1 |
| Tostes, RC | 2 |
| Harvey, AP | 1 |
| Montezano, AC | 1 |
| Hood, KY | 1 |
| Lopes, RA | 1 |
| Rios, F | 1 |
| Ceravolo, G | 1 |
| Graham, D | 1 |
| Touyz, RM | 1 |
| Gkaliagkousi, E | 1 |
| Anyfanti, P | 1 |
| Triantafyllou, A | 1 |
| Gavriilaki, E | 1 |
| Nikolaidou, B | 1 |
| Lazaridis, A | 1 |
| Vamvakis, A | 1 |
| Douma, S | 1 |
| Guo, M | 1 |
| Zhou, C | 1 |
| Xu, G | 1 |
| Tang, L | 1 |
| Ruan, Y | 1 |
| Yu, Y | 1 |
| Lin, X | 1 |
| Wu, D | 1 |
| Chen, H | 1 |
| Yu, P | 1 |
| Jin, L | 1 |
| Wang, Y | 1 |
| Wu, Y | 1 |
| Ullah, K | 1 |
| Rahman, TU | 1 |
| Liu, X | 1 |
| Sheng, J | 1 |
| Chan, HC | 1 |
| Huang, H | 1 |
| McGraw, AP | 2 |
| McCurley, A | 1 |
| Preston, IR | 1 |
| Lu, ZH | 1 |
| Zhu, XX | 1 |
| Tang, ZQ | 1 |
| Yang, GQ | 1 |
| Du, J | 1 |
| Wang, XL | 1 |
| Yang, JZ | 1 |
| Gu, WJ | 1 |
| Guo, QH | 1 |
| Jin, N | 1 |
| Yang, LJ | 1 |
| Ba, JM | 1 |
| Dou, JT | 1 |
| Mu, YM | 1 |
| Liao, CW | 1 |
| Lin, LY | 1 |
| Hung, CS | 1 |
| Lin, YT | 1 |
| Chang, YY | 1 |
| Wang, SM | 1 |
| Wu, VC | 2 |
| Wu, KD | 2 |
| Ho, YL | 1 |
| Satoh, F | 1 |
| Lin, YH | 2 |
| Bruder-Nascimento, T | 1 |
| Ferreira, NS | 1 |
| Zanotto, CZ | 1 |
| Ramalho, F | 1 |
| Pequeno, IO | 1 |
| Olivon, VC | 1 |
| Neves, KB | 1 |
| Alves-Lopes, R | 1 |
| Campos, E | 1 |
| Silva, CA | 1 |
| Fazan, R | 1 |
| Carlos, D | 1 |
| Mestriner, FL | 1 |
| Prado, D | 1 |
| Pereira, FV | 1 |
| Braga, T | 1 |
| Luiz, JP | 1 |
| Cau, SB | 1 |
| Elias, PC | 1 |
| Moreira, AC | 1 |
| Câmara, NO | 1 |
| Zamboni, DS | 1 |
| Alves-Filho, JC | 1 |
| González-Pérez, P | 1 |
| Stiefel, P | 1 |
| Min, LJ | 1 |
| Mogi, M | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Newfell, BG | 2 |
| Aronovitz, M | 1 |
| Mohammad, NN | 1 |
| Perreault, RE | 1 |
| Carmeliet, P | 1 |
| Ehsan, A | 1 |
| Mendelsohn, ME | 2 |
| Lo, SC | 1 |
| Chen, YL | 1 |
| Huang, PH | 1 |
| Tsai, CT | 1 |
| Liang, CJ | 1 |
| Kuo, CC | 1 |
| Kuo, YS | 1 |
| Lee, BC | 1 |
| Wu, EL | 1 |
| Sun, YY | 1 |
| Lin, SL | 1 |
| Chen, JW | 1 |
| Lin, SJ | 1 |
| Luther, JM | 1 |
| Luo, P | 1 |
| Wang, Z | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Fogo, AB | 1 |
| Brown, NJ | 1 |
| Hillaert, MA | 1 |
| Lentjes, EG | 1 |
| Kemperman, H | 1 |
| van der Graaf, Y | 1 |
| Nathoe, HM | 1 |
| Beygui, F | 1 |
| Montalescot, G | 1 |
| Doevendans, PA | 1 |
| Wassink, AM | 1 |
| van Belle, E | 1 |
| Brem, AS | 1 |
| Fiebeler, A | 1 |
| Haller, H | 1 |
| DAVIS, JO | 1 |
| PECHET, MM | 1 |
| BALL, WC | 1 |
| GOODKIND, MJ | 1 |
| WARTER, J | 1 |
| SCHWARTZ, J | 1 |
| BLOCH, R | 1 |
| CARA, U | 1 |
| GIBERTI, A | 1 |
| BIGLIERI, EG | 1 |
| SILTANEN, P | 1 |
| SIPILA, W | 1 |
| MASSON, GM | 1 |
| MIKASA, A | 1 |
| YASUDA, H | 1 |
| Dawson, A | 1 |
| Davies, JI | 1 |
| Struthers, AD | 2 |
| Tintut, Y | 1 |
| Demer, LL | 1 |
| de Solís, AJ | 1 |
| González-Pacheco, FR | 1 |
| Deudero, JJ | 1 |
| Neria, F | 1 |
| Calabia, O | 1 |
| Fernández-Sánchez, R | 1 |
| Caramelo, C | 1 |
| Xavier, FE | 1 |
| Aras-López, R | 1 |
| Arroyo-Villa, I | 1 |
| del Campo, L | 1 |
| Salaices, M | 1 |
| Rossoni, LV | 1 |
| Ferrer, M | 1 |
| Balfagón, G | 1 |
| Kirkendall, WM | 1 |
| Overturf, ML | 1 |
| Druilhet, RE | 1 |
| Van Vliet, AA | 1 |
| Kröger, R | 1 |
| Dubbelman, R | 1 |
| Ten Bokkel-Huinink, WW | 1 |
| Lajemi, M | 1 |
| Gautier, S | 1 |
| Benetos, A | 1 |
| Duprez, D | 1 |
| De Buyzere, M | 1 |
| Rietzschel, ER | 1 |
| Clement, DL | 1 |
| Rocha, R | 1 |
| Stier, CT | 1 |
| Kifor, I | 1 |
| Ochoa-Maya, MR | 1 |
| Rennke, HG | 1 |
| Williams, GH | 1 |
| Adler, GK | 1 |
| Kostiuk, IF | 1 |
| Suc, JM | 1 |
| Perez-Stable, EC | 1 |
| Materson, BJ | 1 |
| Liddle, GW | 1 |
| Sims, EA | 1 |
| MacKay, BR | 1 |
| Shirai, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes[NCT01687998] | Phase 3 | 12,092 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Study termination due to insufficient efficacy.) | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 857 |
| Placebo | 867 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 690 |
| Placebo | 691 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 571 |
| Placebo | 570 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline to Study Completion (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 779 |
| Placebo | 776 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 437 |
| Placebo | 453 |
(NCT01687998)
Timeframe: Baseline, 3 Months
| Intervention | percent (Mean) | |
|---|---|---|
| LDL-C | HDL-C | |
| Evacetrapib | -31.12 | 133.18 |
| Placebo | 5.99 | 1.63 |
9 reviews available for aldosterone and Vascular Diseases
| Article | Year |
|---|---|
Mineralocorticoid Receptor and Endothelial Dysfunction in Hypertension.
Topics: Aldosterone; Animals; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Epithelial S | 2019 |
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Disease Progression; | 2013 |
Signaling mechanisms of angiotensin II in regulating vascular senescence.
Topics: Aging; Aldosterone; Angiotensin II; Animals; Humans; Receptor, Angiotensin, Type 1; Renin-Angiotensi | 2009 |
Participation of the mineralocorticoid receptor in cardiac and vascular remodeling.
Topics: Aldosterone; Animals; Heart Diseases; Humans; Kidney; Mice; Mineralocorticoid Receptor Antagonists; | 2003 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
Aldosterone-induced vasculopathy.
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Fibrosis; Heart Arrest; Heart Failure; Humans; | 2004 |
[Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants].
Topics: Aldosterone; Arteries; Cardiovascular Diseases; Elasticity; Humans; Renin-Angiotensin System; Risk F | 1999 |
Aldosterone and vascular damage.
Topics: Adrenal Cortex; Aldosterone; Arteries; Autonomic Nervous System; Baroreflex; Body Water; Compliance; | 2000 |
[Malignant arterial hypertension].
Topics: Aldosterone; Angiotensin II; Antihypertensive Agents; Endarteritis; Female; Humans; Hypertension, Ma | 1975 |
3 trials available for aldosterone and Vascular Diseases
| Article | Year |
|---|---|
Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease.
Topics: Aldosterone; Anemia, Sickle Cell; Animals; Disease Models, Animal; Endothelial Cells; Endothelin-1; | 2023 |
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Double-Blind | 2019 |
Treatment of patients with IVCS and gross oedema and ascites with diuretic combination and ACE-inhibitors: relation to baseline PRA and PAC.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Ascites; Captopril; Diuretics; D | 1995 |
30 other studies available for aldosterone and Vascular Diseases
| Article | Year |
|---|---|
Selective deletion of endothelial mineralocorticoid receptor protects from vascular dysfunction in sodium-restricted female mice.
Topics: Adrenal Glands; Aldosterone; Animals; Cyclooxygenase 2; Cytochrome P-450 CYP11B2; Diet, Sodium-Restr | 2020 |
Aldosterone Negatively Regulates Nrf2 Activity: An Additional Mechanism Contributing to Oxidative Stress and Vascular Dysfunction by Aldosterone.
Topics: Aldosterone; Animals; Endothelium, Vascular; Kelch-Like ECH-Associated Protein 1; Male; Mice; Mice, | 2021 |
Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis.
Topics: Acetylcholine; Aldosterone; Animals; Aorta; Blood Pressure; Galectin 3; Hypertension; Male; Mesenter | 2017 |
Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals.
Topics: Adult; Albuminuria; Aldosterone; Blood Pressure; Correlation of Data; Female; Humans; Hypertension; | 2018 |
An alternative splicing variant of mineralocorticoid receptor discovered in preeclampsia tissues and its effect on endothelial dysfunction.
Topics: Adult; Aldosterone; Alternative Splicing; Blood Pressure; DNA, Complementary; Endothelial Cells; Fem | 2020 |
Female sex hormones are associated with the reduction of serum sodium and hypertension complications in patients with aldosterone-producing adenoma.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Biomarkers; Cerebrovascular Disorders; | 2013 |
Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.
Topics: Adenoma; Adrenalectomy; Adult; Aldosterone; Ankle Brachial Index; Female; Hemodynamics; Humans; Hype | 2016 |
NLRP3 Inflammasome Mediates Aldosterone-Induced Vascular Damage.
Topics: Acetylcholine; Aldosterone; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Caspase 1; Huma | 2016 |
Increased carotid intima-media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration.
Topics: Aldosterone; Carotid Arteries; Humans; Hypertension; Renin; Tunica Intima; Tunica Media; Ultrasonogr | 2008 |
Placental growth factor mediates aldosterone-dependent vascular injury in mice.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Clinical Trials as Topic; Humans; Male; Mice; | 2010 |
Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis.
Topics: Adenoma; Adult; Aged; Aldosterone; Apoptosis; Arteries; Biomarkers; C-Reactive Protein; Cell Count; | 2011 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease.
Topics: Aged; Aldosterone; Atherosclerosis; Biomarkers; Cohort Studies; Coronary Artery Disease; Female; Fol | 2013 |
Targeting activated mineralocorticoid receptor: Occam's razor revisited.
Topics: Aldosterone; Angiotensin II; Animals; Heart Diseases; Kidney Diseases; Mineralocorticoid Receptor An | 2012 |
Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava constriction.
Topics: Aldosterone; Animals; Constriction; Constriction, Pathologic; Dogs; Heart Failure; Vascular Diseases | 1957 |
[Secondary hyperaldosteronism in the course of arterial hypertension].
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Vascular Diseases | 1960 |
[Mineralo-corticoid activity in arteriopathic patients subjected to lumbar gangliectomy].
Topics: Adrenal Cortex Hormones; Aldosterone; Arteriosclerosis Obliterans; Humans; Lumbosacral Region; Sympa | 1962 |
HYPOKALEMIC ALKALOSIS EDEMA WITH INCREASED DESOXYCORTICOSTERONE EXCRETION.
Topics: Adrenalectomy; Aldosterone; Alkalosis; Angiotensins; Bartter Syndrome; Blood Volume; Cushing Syndrom | 1965 |
Hypertension associated with hypokalemia and alkalosis simulating primary hyperaldosteronism: report of a case.
Topics: Aldosterone; Alkalosis; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Potassium; Vascular D | 1959 |
Experimental vascular disease elicited by aldosterone and renin.
Topics: Aldosterone; Angiotensin Amide; Blood Vessels; Disease; Humans; Hypertension; Renin; Vascular Diseas | 1962 |
Mineralocorticoid receptor activation promotes vascular cell calcification.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Adrenal Cortex Hormones; Aldosterone; Alkaline Phosphat | 2007 |
[Aldosterone increases in vitro vascular calcification].
Topics: Aldosterone; Calcinosis; Cells, Cultured; Humans; Muscle, Smooth, Vascular; Vascular Diseases | 2008 |
Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aldosterone; Animals; Blotting, | 2008 |
Is renin a risk factor?
Topics: Aldosterone; Animals; Aortic Diseases; Arteriosclerosis; Cholesterol, Dietary; Diet, Atherogenic; Hy | 1981 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
[Humoral pressor and depressor factors in vibration disease].
Topics: Adult; Aldosterone; Animals; Catecholamines; Circadian Rhythm; Humans; Kininogens; Middle Aged; Neur | 1976 |
Workup of the newly discovered hypertensive patient.
Topics: Adult; Aldosterone; Angiotensin II; Cardiac Output; Cerebrovascular Disorders; Contraceptives, Oral; | 1975 |
Idiopathic oedema.
Topics: Adrenal Glands; Aldosterone; Diuretics; Edema; Female; Gonadal Steroid Hormones; Humans; Plasma Volu | 1972 |
Proceedings: Blueprints for the solution of three endocrinological enigmas. The Sir Henry Dale Lecture for 1973.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Blood Glucose; Ca | 1973 |
The relation of capillary angiopathy and diabetes mellitus to idiopathic edema.
Topics: Adult; Aldosterone; Basement Membrane; Blood Chemical Analysis; Capillaries; Capillary Permeability; | 1965 |